Industry Innovations

The guidelines exist. The evidence is clear. So why does the gap between what we know and what we do in practice persist? In this Industry Innovations episode, guest host Daniel E. Soffer, MD, MNLA sits down with Nihar R. Desai, MD, MPH, FNLA and Jessica M. Pena, MD, MPH, FNLA to tackle one of the most pressing challenges in cardiovascular medicine: implementation.Together, this trio of experts shares their perspectives on the real-world barriers to translating the 2026 dyslipidemia guidelines into everyday clinical practice. This candid conversation touches on where the field stands today, what they hope to see change, and what the future of ASCVD management looks like.This episode's topic comes courtesy of Amgen, a member of the NLA Industry Council.Watch this episode on YouTube HERE.

When two past NLA Presidents and seasoned podcast hosts sit down together, the conversation is bound to be something special. In this Industry Innovations episode, Peter H. Jones, MD, MNLA is joined by fellow lipidologist Alan S. Brown, MD, MHA, MNLA for an in-depth discussion on one of the most clinically nuanced topics in lipid management: statin intolerance. Together, these two experts bring a combined wealth of experience to the table — tackling statin-attributed side effects head-on, exploring how the latest guidelines address intolerance, and walking through how to navigate patient concerns with confidence. From practical strategies for managing statin-related symptoms to the growing role of non-statin therapies in achieving LDL-lowering goals, this episode is packed with actionable insights for any clinician managing patients with dyslipidemia. This episode's topic comes courtesy of Esperion, a member of the NLA Industry Council.Watch the video episode on YouTube: https://youtu.be/4RY3_0YAkvU

In this compelling episode of NLA Industry Innovations, host Kevin Maki, PhD, MNLA sits down with renowned lipidologist and clinical researcher Michael Davidson, MD, MNLA to explore the complex world of pharmaceutical development. Together, they unpack the science behind medical therapies—from early-stage innovation to clinical trials—and dive into the strategic decisions that shape which treatments make it to market.Dr. Davidson offers a behind-the-scenes look at how pharmaceutical companies weigh scientific promise, regulatory pathways, market dynamics, and patient needs when developing new therapies. The conversation also touches on the challenges of balancing innovation with accessibility, and why some promising treatments never reach the shelves.Whether you're a clinician, researcher, or industry insider, this episode provides valuable insights into the forces driving therapeutic advancement in lipidology and beyond.Sponsored by New Amsterdam PharmaFeaturing Michael H. Davidson, MD, ABCL, MNLANewAmsterdam Pharma,Naarden, The NetherlandsLipid Clinic, Pritzker School of Medicine, University of Chicago,Chicago, IL, USAGuest Host:Kevin Maki, PhD, CLS, MNLAChief Scientist, Midwest Biomedical ResearchAdjunct Professor, Dean’s Eminent ScholarIndiana University School of Public HealthBloomington, INClick HERE to watch the video of this podcast

In this episode of Industry Innovations, host Dr. Alan Brown sits down with Dr. Lisa Christopher-Stine, a leading expert in autoimmune muscle disease, to explore the often-overlooked condition of statin-induced autoimmune myopathy. Together, they discuss how to recognize, diagnose, and manage this rare but serious complication, offering key takeaways for clinicians prescribing statins and managing lipid disorders. Sponsored by Werfen

Dr. Bruce Given shares insights into Arrowhead Pharmaceuticals’ innovative approach to siRNA therapeutics and the company’s growing role in lipid management and cardiovascular care. Hosted by Dr. Peter Jones, this conversation highlights the intersection of clinical need and next-gen molecular science. 

In this episode of Industry Innovations, host Dr. Peter Jones is joined by Dr. Guy Mintz to explore an exciting advancement in cardiovascular care: LODOCO, a low-dose colchicine developed by Agepha Pharma. Backed by robust clinical trial data, LODOCO is an FDA-approved therapy targeting inflammation as a novel approach to reducing the risk of heart attacks. Learn how inflammation contributes to cardiovascular events and why this groundbreaking therapy is redefining prevention strategies. Dr. Mintz discusses the science, the data, and the potential impact of LODOCO on clinical practice, offering valuable insights for clinicians committed to improving patient outcomes. Sponsored by Agepha Pharma